prodcode,dmdcode,gemscriptcode,therapyevents,productname,ingredient,strength,formulation,routeofadministration,bnftext,v12,v13,v14,v15,v16,v17,v18,v19,v20,v21,slashcountinchapter,bnfchapter
41960,134636009,84193020,1,Topotecan 1mg powder for solution for infusion vials,Topotecan hydrochloride,1mg,Powder for solution for infusion,Intravenous,Topoisomerase I Inhibitors,April 2010,10805002,,,,,,,,,0,8010553
47396,427960006,95227020,1,Topotecan 1mg capsules,Topotecan hydrochloride,1mg,Capsule,Oral,Topoisomerase I Inhibitors,June 2012,16224001,,,,,,,,,0,8010553
33227,4802711000001107,84200020,1,Hycamtin 4mg powder for concentrate for solution for infusion vials (Novartis Pharmaceuticals UK Ltd),Topotecan hydrochloride,4mg,Powder for solution for infusion,Intravenous,Topoisomerase I Inhibitors,February 2009,10808001,,,,,,,,,0,8010553
40983,3.60496110000e+16,92941020,0,Irinotecan 40mg/2ml solution for infusion vials,Irinotecan hydrochloride trihydrate,20mg/1ml,Solution for infusion,Intravenous,Topoisomerase I Inhibitors,December 2009,15069001,,,,,,,,,0,8010553
68267,3.60495110000e+16,92943020,0,Irinotecan 100mg/5ml solution for infusion vials,Irinotecan hydrochloride trihydrate,20mg/1ml,Solution for infusion,Intravenous,Topoisomerase I Inhibitors,November 2016,15070001,,,,,,,,,0,8010553
59339,1.78459110000e+16,7399020,0,Irinotecan 40mg/2ml concentrate for solution for infusion vials (Pfizer Ltd),Irinotecan hydrochloride trihydrate,20mg/1ml,Solution for infusion,Intravenous,Topoisomerase I Inhibitors,April 2014,7399020,,,,,,,,,0,8010553
